Safety profile of amifampridine in real-world use: a disproportionality analysis of the FAERS database
Frontiers in Pharmacology · 18.11.2026 · 17
DOI: 10.3389/fphar.2026.2013910 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.11.2026. Verfasst von Chuang Yang und 1 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Amifampridine is the first drug approved specifically for Lambert-Eaton myasthenic syndrome (LEMS), but its safety profile is still not fully understood. This study aimed to systematically detect and characterize post-marketing adverse event signals of amifampridine using the FDA Adverse Event Reporting System (FAERS).
Methods
Case reports from FAERS between Q1 2004 and Q2 2026 were analyzed. Disproportionality analysis was performed using four algorithms: the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-gamma Poisson shrinker (MGPS); only events meeting all four criteria were retained as signals. Time-to-onset (TTO) was analyzed with a Weibull distribution, and sex stratified analyses were conducted.
Results
A total of 2,893 reports involved amifampridine as the primary suspect drug. Most reports came from the United States (98.1%) and were submitted by consumers (82.0%). Signals were concentrated in the nervous and gastrointestinal systems, consistent with known cholinergic toxicity, including oral and pharyngeal paraesthesia, hypoaesthesia, and abdominal discomfort. Notably, a cluster of bladder-related events including hypertonic bladder, bladder pain, bladder spasm, and incontinence was identified that is not listed in the prescribing information. Median TTO was 658 days, and the Weibull shape parameter (β = 0.889, 95% CI 0.840–0.937) indicated an early-failure pattern. Sex-stratified analysis showed distinct reporting patterns between males and females.
Conclusion
Most identified signals were consistent with the established cholinergic toxicity of amifampridine. Previously unreported adverse event signals, such as bladder-related events, were also identified. These findings indicate that long-term monitoring of adverse events associated with amifampridine is necessary to improve patient safety.
Zitieren
APA
Yang, C., & Wang, C. (2026). Safety profile of amifampridine in real-world use: a disproportionality analysis of the FAERS database. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2013910
Vancouver
Yang C, Wang C. Safety profile of amifampridine in real-world use: a disproportionality analysis of the FAERS database. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2013910
BibTeX
@article{Yang2026,
author = {Yang, Chuang and Wang, Chen},
title = {Safety profile of amifampridine in real-world use: a disproportionality analysis of the FAERS database},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.2013910}
}
EUVIMED